Atezolizumab

阿替利珠单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAtezolizumab
Drug Alias Nameatezolizumab阿替利组单抗阿特利珠单抗atezolizumabum阿特珠单抗 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockersCytotoxic T lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsMetastatic breast cancerSkin MelanomaGastroesophageal Junction Neoplasms +[73] 
Global Approved IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Transitional Cell
Approved Indications in ChinaSmall Cell Lung Carcinoma
Original Approved Country/TerritoryUnited States
Original Approved Date2016/05/18
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[67] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteRoche Korea Co LtdUniversity Medical Center Groningen +[37] 
Inactive CompaniesTurnstone Biologics CorpInstitut CurieYale University +[10] 
Active IndicationsSkin MelanomaGastroesophageal Junction NeoplasmsSolid tumours +[52] 
Inactive IndicationsMetastatic breast cancerMyelodysplastic SyndromesKidney Diseases +[21] 

Other Information

ATC CodeL01XC32
Related LinksWikipediaDrugBankKEGG